Hospira Acquisition of Mayne Pharma Clears U.S. Antitrust Review
18 Janeiro 2007 - 5:06PM
PR Newswire (US)
-- Companies Anticipate Closing the Transaction the First Week of
February -- LAKE FOREST, Ill., Jan. 18 /PRNewswire-FirstCall/ --
Hospira, Inc. (NYSE:HSP), a leading global hospital products
company, and Mayne Pharma Limited (ASX:MYP), a leading
Australia-based specialty injectable pharmaceuticals company, today
announced that, subject to the divestiture of certain overlapping
products, the U.S. Federal Trade Commission (FTC) has cleared the
way for Hospira to proceed with its proposed acquisition of Mayne.
The product divestitures are not material to the transaction.
"We're pleased to receive FTC clearance and move closer to becoming
the world's leader in generic injectable pharmaceuticals," said
Christopher B. Begley, chief executive officer, Hospira. "Following
the combination of our companies, we will be even better positioned
to help reduce the overall costs of healthcare worldwide." "We
welcome the clearance of the final step towards Mayne Pharma
shareholders realizing excellent value for their investment, as
their company moves closer to joining one of the world's leading
global pharmaceutical and medication delivery companies," said
Peter Willcox, chairman, Mayne Pharma. Hospira and Mayne expect
that, subject to final court approvals and customary closing
conditions, the transaction will be completed the first week of
February. About Hospira Hospira, Inc. is a global specialty
pharmaceutical and medication delivery company dedicated to
Advancing Wellness(TM) by developing, manufacturing and marketing
products that help improve the productivity, safety and efficacy of
patient care. With 70 years of service to the hospital industry,
Hospira's portfolio includes one of the industry's broadest lines
of generic acute-care injectables, which help address the high cost
of proprietary pharmaceuticals; integrated solutions for medication
management and infusion therapy; and the leading U.S. injectable
contract manufacturing business. Headquartered north of Chicago in
Lake Forest, Ill., Hospira has approximately 13,000 employees and
14 manufacturing facilities worldwide. Hospira's news releases and
other information can be found at http://www.hospira.com/. About
Mayne Pharma Mayne Pharma Limited is a specialty pharmaceutical
company focused on developing, manufacturing and selling a
comprehensive range of products to oncology customers in more than
65 countries around the world. The company seeks to augment its
growth by accessing additional marketed or development- stage
products either through acquisition or partnership. Mayne Pharma
generated sales of more than AUD$800 million in its financial year
ended June 30, 2006, and is listed on the Australian Stock Exchange
under the symbol 'MYP.' For more information about Mayne Pharma,
please visit http://www.maynepharma.com/. Private Securities
Litigation Reform Act of 1995 -- A Caution Concerning
Forward-Looking Statements This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
regarding the expected completion date of Hospira's acquisition of
Mayne Pharma and other statements regarding Hospira's goals and
strategy. Hospira cautions that these forward-looking statements
are subject to risks and uncertainties that may cause actual
results to differ materially from those indicated in the
forward-looking statements. Risks and uncertainties relating to
Hospira's proposed acquisition of Mayne Pharma that may cause
actual results to be materially different from expectations are
discussed under the heading "Risk Factors -- Risks Relating to
Proposed or Pending Acquisitions" in Hospira's Quarterly Report on
Form 10-Q for the quarterly period ended Sept. 30, 2006, and are
incorporated by reference. Economic, competitive, governmental,
technological and other factors that may affect Hospira's
operations and cause actual results to be materially different from
expectation include the risks, uncertainties and factors discussed
under the headings "Risk Factors" and "Management's Discussion and
Analysis of Financial Condition and Results of Operations" in
Hospira's Annual Report on Form 10-K for the year ended Dec. 31,
2005, and subsequent Quarterly Reports on Form 10- Q, filed with
the Securities and Exchange Commission, which are incorporated by
reference. Hospira undertakes no obligation to release publicly any
revisions to forward-looking statements as the result of subsequent
events or developments.
http://www.newscom.com/cgi-bin/prnh/20040503/HSPLOGO
http://photoarchive.ap.org/ DATASOURCE: Hospira, Inc. CONTACT:
Hospira Contacts, U.S. Media, Stacey Eisen, +1-224-212-2276, or
Australian Media, Tony Rasman, Fleishman-Hillard Australia, +61 418
208 770, or Financial Community, Lynn McHugh, +1-224-212-2363; or
Mayne Pharma Contacts, Media, Sue Cato, Cato Counsel, +61 419 282
319, or Matt Horan, Cato Counsel, +61 403 934 958, or Financial
Community, Andrew Rowe, +44 20 7420 8426, or +44 7920 598 353
(mobile) Web site: http://www.hospira.com/
http://www.maynepharma.com/
Copyright
Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jul 2024 até Ago 2024
Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Ago 2023 até Ago 2024